Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Digilab BioVisioN is a specialized life sciences company focused on peptidomics and biomarker discovery. The entity was established following Digilab's acquisition of the German firm BioVisioN AG, integrating advanced peptide profiling technologies with laboratory automation. The company's proprietary Pepti-Map platform allows for the comprehensive analysis of peptides in blood and other biological fluids, facilitating the discovery of novel biomarkers for diseases such as cancer and diabetes. In addition to its research services, Digilab provides high-precision liquid handling and sample preparation instruments to the pharmaceutical and biotechnology industries. Digilab BioVisioN supports global pharmaceutical and academic partners in accelerating drug discovery and developing diagnostic tools.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Digilab BioVisioN.